Digestive tract disease
Conditions
Interventions
Experimental group (Collection and Bioinformatics Analysis of Digestive Fluid and Fecal Samples from IBD and colorectal cancer patients):None
Control group (Collection and Bioinformatics Analysis of Digestive Fluid and Fecal Samples from Healthy Subjects):None
Sponsors
Wuhan Union Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 18-60 years old; 2. Patients diagnosed with IBD, colorectal cancer, or healthy individuals with normal endoscopic screening results, confirmed through imaging, endoscopy, and histopathological examinations; 3. Good compliance, able to cooperate and complete the entire clinical trial (routine endoscopy, imaging, and life-style examinations) as well as subsequent follow-ups; 4. Able to understand and accept the research protocol, voluntarily signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1. History of alcohol consumption within the past 2 weeks or smoking within the past 6 months; 2. History of taking live bacterial preparations within the past 3 months or using antibiotics within the past 6 months; 3. Known or suspected gastrointestinal obstruction, stenosis, or fistula; 4. Presence of concomitant diseases that can alter the gastrointestinal microbiome (such as malabsorption syndrome); 5. Patients who have undergone extensive colectomy, resection of =3 segments of the small intestine, short bowel syndrome, ileostomy or colostomy, or those requiring long-term nasogastric feeding; 6. Severe infections (such as severe hepatitis, tuberculosis, pneumonia, and urinary tract infections) or other life-threatening diseases; 7. Immune dysfunction caused by genetic diseases or other conditions; 8. Pregnant or lactating women; 9. Inability to swallow the sampling capsule endoscope; 10. Patients with implanted cardiac pacemakers or other implanted electronic medical devices; 11. Patients with implanted metal parts that may be magnetized; 12. Patients with a scheduled MRI examination within 1 week after swallowing the capsule endoscope; 13. Concurrent participation in another clinical trial of drugs or devices; 14. Voluntary withdrawal from the study; 15. Inability to assume legal responsibility or those whose participation in the study is hindered by medical or ethical reasons; 16. Other conditions deemed unsuitable for this study by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Digestive fluid intestinal flora, metabolites; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fecal intestinal flora, metabolites; | — |
Countries
China
Contacts
Public ContactRong Lin
Wuhan Union Hospital
Outcome results
None listed